NZ589670A
(en)
|
2004-12-20 |
2013-01-25 |
Genentech Inc |
Pyrrolidine inhibitors of iap
|
US7745636B2
(en)
|
2006-08-11 |
2010-06-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8303944B2
(en)
*
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100055071A1
(en)
*
|
2006-11-21 |
2010-03-04 |
Martin Robert Leivers |
Anti-Viral Compounds
|
NZ598890A
(en)
*
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
EP2494991A1
(en)
|
2007-05-04 |
2012-09-05 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of HCV infection
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ITMI20071012A1
(it)
*
|
2007-05-18 |
2008-11-19 |
St Microelectronics Srl |
Dispositivo di memoria migliorato a veloce programmazione
|
EP2532643A1
(en)
|
2007-06-08 |
2012-12-12 |
MannKind Corporation |
IRE-1A Inhibitors
|
AR067413A1
(es)
*
|
2007-07-05 |
2009-10-07 |
Genentech Inc |
Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
|
US7728027B2
(en)
*
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
*
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
CA2711957C
(en)
|
2007-10-11 |
2019-03-19 |
The Regents Of The University Of California |
Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments
|
JP5314053B2
(ja)
*
|
2008-02-12 |
2013-10-16 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US8093243B2
(en)
|
2008-02-12 |
2012-01-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2009102325A1
(en)
*
|
2008-02-13 |
2009-08-20 |
Bristol-Myers Squibb Company |
Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
|
US7704992B2
(en)
*
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
NZ590550A
(en)
|
2008-08-02 |
2013-05-31 |
Genentech Inc |
Inhibitors of Apoptosis (IAP) for treating cancer
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010042834A1
(en)
*
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
SI2373172T1
(sl)
*
|
2008-12-03 |
2013-12-31 |
Presidio Pharmaceuticals, Inc. |
Inhibitorji HCV NS5A
|
KR20110098779A
(ko)
|
2008-12-03 |
2011-09-01 |
프레시디오 파마슈티칼스, 인코포레이티드 |
Hcv ns5a의 억제제
|
CN102264737A
(zh)
|
2008-12-23 |
2011-11-30 |
雅培制药有限公司 |
抗病毒化合物
|
MX2011006333A
(es)
|
2008-12-23 |
2011-06-27 |
Abbott Lab |
Compuestos antivirales.
|
WO2010091413A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
US8242156B2
(en)
|
2009-02-17 |
2012-08-14 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
TWI438200B
(zh)
*
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8394968B2
(en)
|
2009-02-17 |
2013-03-12 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8188132B2
(en)
|
2009-02-17 |
2012-05-29 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
US8637561B2
(en)
|
2009-02-17 |
2014-01-28 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole derivatives
|
US8420686B2
(en)
|
2009-02-17 |
2013-04-16 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole antivirals
|
CA2753313A1
(en)
*
|
2009-02-23 |
2010-08-26 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2010094977A1
(en)
|
2009-02-23 |
2010-08-26 |
Arrow Therapeutics Limited |
Novel biphenyl compounds useful for the treatment of hepatitis c
|
US9765087B2
(en)
|
2009-02-27 |
2017-09-19 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US10752611B2
(en)
|
2009-02-27 |
2020-08-25 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8426458B2
(en)
|
2009-02-27 |
2013-04-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C Virus inhibitors
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8673954B2
(en)
|
2009-02-27 |
2014-03-18 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
SG174146A1
(en)
|
2009-02-27 |
2011-10-28 |
Enanta Pharm Inc |
Hepatitis c virus inhibitors
|
US8507522B2
(en)
|
2009-03-06 |
2013-08-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
PE20120773A1
(es)
*
|
2009-03-27 |
2012-07-19 |
Presidio Pharmaceuticals Inc |
Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
|
EP2410841A4
(en)
|
2009-03-27 |
2012-10-24 |
Presidio Pharmaceuticals Inc |
SUBSTITUTED BICYCLIC HCV INHIBITORS
|
TWI476190B
(zh)
*
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW201038559A
(en)
*
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2419404B1
(en)
*
|
2009-04-15 |
2015-11-04 |
AbbVie Inc. |
Anti-viral compounds
|
CA2759142A1
(en)
|
2009-04-24 |
2010-10-28 |
Tibotec Pharmaceuticals |
Diaryl ethers
|
WO2010132538A1
(en)
*
|
2009-05-12 |
2010-11-18 |
Schering Corporation |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
AU2014203349B2
(en)
*
|
2009-05-13 |
2014-11-27 |
Gilead Pharmasset Llc |
Antiviral compounds
|
JP5582662B2
(ja)
*
|
2009-05-13 |
2014-09-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
AU2013202666B2
(en)
*
|
2009-05-13 |
2015-07-16 |
Gilead Pharmasset Llc |
Antiviral compounds
|
US8211928B2
(en)
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8138215B2
(en)
*
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8980920B2
(en)
*
|
2009-05-29 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
|
US8772505B2
(en)
*
|
2009-05-29 |
2014-07-08 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
|
US8716454B2
(en)
|
2009-06-11 |
2014-05-06 |
Abbvie Inc. |
Solid compositions
|
ES2565536T3
(es)
*
|
2009-06-11 |
2016-04-05 |
Abbvie Bahamas Ltd. |
Heterociclos trisustituidos como inhibidores de la replicación del virus de la Hepatitis C VHC
|
AU2012203474B2
(en)
*
|
2009-06-11 |
2014-09-18 |
Abbvie Ireland Unlimited Company |
Anti-Viral Compounds
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
US8221737B2
(en)
|
2009-06-16 |
2012-07-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8609648B2
(en)
|
2009-07-02 |
2013-12-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
JP2012533569A
(ja)
|
2009-07-16 |
2012-12-27 |
ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド |
フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
|
RU2538507C2
(ru)
|
2009-08-07 |
2015-01-10 |
Тиботек Фармасьютикалз |
Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
|
CA2768638A1
(en)
|
2009-08-07 |
2011-02-10 |
Tibotec Pharmaceuticals |
Bis-benzimidazole derivatives as hepatitis c virus inhibitors
|
US20120172368A1
(en)
|
2009-09-03 |
2012-07-05 |
Koen Vandyck |
Bis-Benzimidazole Derivatives
|
PE20120993A1
(es)
*
|
2009-09-04 |
2012-08-22 |
Janssen Pharmaceuticals Inc |
Derivados bifenilicos como antivirales
|
WO2011031904A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc |
Hepatitis c virus inhibitors
|
US8927709B2
(en)
*
|
2009-09-11 |
2015-01-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011031934A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US8822700B2
(en)
*
|
2009-09-11 |
2014-09-02 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8759332B2
(en)
*
|
2009-09-11 |
2014-06-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8815928B2
(en)
|
2009-09-11 |
2014-08-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8703938B2
(en)
*
|
2009-09-11 |
2014-04-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
UA108211C2
(uk)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензімідазолімідазольні похідні
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20120276047A1
(en)
|
2009-11-25 |
2012-11-01 |
Rosenblum Stuart B |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
US20110137633A1
(en)
*
|
2009-12-03 |
2011-06-09 |
Abbott Laboratories |
Anti-viral compounds and methods of identifying the same
|
CN102482269B
(zh)
*
|
2009-12-04 |
2015-07-29 |
财团法人卫生研究院 |
脯氨酸衍生物
|
US8653070B2
(en)
*
|
2009-12-14 |
2014-02-18 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5536229B2
(ja)
|
2009-12-18 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv併用療法
|
US20110152246A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
JP2013515068A
(ja)
|
2009-12-22 |
2013-05-02 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
|
MX2012007420A
(es)
*
|
2009-12-24 |
2012-07-23 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones de flavivirus.
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011091417A1
(en)
|
2010-01-25 |
2011-07-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011091532A1
(en)
*
|
2010-01-28 |
2011-08-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
US8178531B2
(en)
|
2010-02-23 |
2012-05-15 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US8623814B2
(en)
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US9060971B2
(en)
|
2010-03-04 |
2015-06-23 |
Enanta Pharmaceuticals, Inc. |
Combination pharmaceutical agents as inhibitors of HCV replication
|
MX2012010392A
(es)
|
2010-03-09 |
2012-10-03 |
Merck Sharp & Dohme |
Compuesto de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales.
|
JP2013522377A
(ja)
*
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
JP2013522375A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
TW201141857A
(en)
*
|
2010-03-24 |
2011-12-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
EP2609923B1
(en)
|
2010-03-31 |
2017-05-24 |
Gilead Pharmasset LLC |
Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
|
US9127021B2
(en)
|
2010-04-09 |
2015-09-08 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US9125904B1
(en)
|
2010-05-11 |
2015-09-08 |
Achillion Pharmaceuticals, Inc. |
Biphenyl imidazoles and related compounds useful for treating HCV infections
|
WO2011146401A1
(en)
*
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
CA2800509A1
(en)
*
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
EP2575819A4
(en)
|
2010-06-04 |
2013-11-27 |
Enanta Pharm Inc |
INHIBITORS OF HEPATITIS C VIRUS
|
NZ605440A
(en)
*
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
UY33473A
(es)
|
2010-06-28 |
2012-01-31 |
Vertex Pharma |
Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
|
EP2585448A1
(en)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
EP2593565A4
(en)
*
|
2010-07-16 |
2013-12-04 |
Bristol Myers Squibb Co |
METHODS FOR IDENTIFYING COMBINATIONS OF NS5A TARGETING COMPOUNDS THAT SYNERGISTICALLY WORK TO INHIBIT THE REPLICATION OF HEPATITIS C VIRUS
|
US8815849B2
(en)
|
2010-07-26 |
2014-08-26 |
Janssen R&D Ireland |
Hetero-bicyclic derivatives as HCV inhibitors
|
US20140377223A1
(en)
|
2010-07-26 |
2014-12-25 |
Joseph A. Kozlowski |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
US20120196794A1
(en)
*
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
US20120195857A1
(en)
*
|
2010-08-12 |
2012-08-02 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8697704B2
(en)
|
2010-08-12 |
2014-04-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
JP2013534249A
(ja)
|
2010-08-17 |
2013-09-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
|
EP2616461A4
(en)
*
|
2010-08-26 |
2014-03-26 |
Rfs Pharma Llc |
POWERFUL AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
|
US8822520B2
(en)
|
2010-09-22 |
2014-09-02 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
BR112013008148A2
(pt)
*
|
2010-09-24 |
2016-08-09 |
Bristol Myers Squibb Co |
"inibidores do vírus da hepatite c".
|
WO2012050918A2
(en)
|
2010-09-29 |
2012-04-19 |
Presidio Pharmaceutical, Inc. |
Tricyclic fused ring inhibitors of hepatitis c
|
AU2011314168A1
(en)
|
2010-09-29 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
TWI621611B
(zh)
*
|
2010-10-13 |
2018-04-21 |
艾伯維愛爾蘭無限公司 |
抗病毒化合物
|
AU2014203655B2
(en)
*
|
2010-10-13 |
2016-07-07 |
Abbvie Ireland Unlimited Company |
Anti-viral compounds
|
WO2012048421A1
(en)
*
|
2010-10-14 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
CN103269586B
(zh)
|
2010-10-26 |
2015-07-15 |
普雷西迪奥制药公司 |
丙型肝炎病毒抑制剂
|
JP5891235B2
(ja)
*
|
2010-11-04 |
2016-03-22 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
C型肝炎ウイルスの新規阻害剤
|
CA3102625C
(en)
*
|
2010-11-17 |
2024-02-20 |
Gilead Pharmasset Llc |
Antiviral compounds
|
RU2452735C1
(ru)
*
|
2010-11-30 |
2012-06-10 |
Александр Васильевич Иващенко |
Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
EP2651928A4
(en)
*
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
US20150158909A1
(en)
*
|
2010-12-15 |
2015-06-11 |
Abbevie Inc. |
Anti-viral compounds
|
WO2012087976A2
(en)
*
|
2010-12-21 |
2012-06-28 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
EP2655362A1
(en)
|
2010-12-22 |
2013-10-30 |
Abbvie Inc. |
Hepatitis c inhibitors and uses thereof
|
US8552047B2
(en)
*
|
2011-02-07 |
2013-10-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
US8835456B1
(en)
|
2011-03-18 |
2014-09-16 |
Achillion Pharmaceuticals, Inc. |
NS5A inhibitors useful for treating HCV
|
US9546160B2
(en)
|
2011-05-12 |
2017-01-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
CN103687489A
(zh)
|
2011-05-18 |
2014-03-26 |
埃南塔制药公司 |
制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
|
CA2837481A1
(en)
|
2011-05-27 |
2012-12-06 |
Achillion Pharmaceuticals, Inc. |
Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
|
US20120328565A1
(en)
|
2011-06-24 |
2012-12-27 |
Brinkman John A |
Antiviral compounds
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
AU2012286853A1
(en)
|
2011-07-26 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
Thiophene compounds
|
SG2014010490A
(en)
*
|
2011-08-24 |
2014-04-28 |
Glaxosmithkline Llc |
Combination treatments for hepatitis c
|
WO2013030750A1
(en)
|
2011-09-01 |
2013-03-07 |
Lupin Limited |
Antiviral compounds
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
|
HUE036588T2
(hu)
|
2011-09-16 |
2018-07-30 |
Gilead Pharmasset Llc |
Eljárások HCV kezelésére
|
GB201116559D0
(en)
*
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
WO2013053657A1
(en)
|
2011-10-10 |
2013-04-18 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
UY34402A
(es)
|
2011-10-21 |
2013-05-31 |
Abbvie Inc |
Métodos para el tratamiento de hcv
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
CH707030B1
(de)
|
2011-10-21 |
2015-03-13 |
Abbvie Inc |
Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
CN103946220B
(zh)
|
2011-11-03 |
2017-12-22 |
施万生物制药研发Ip有限责任公司 |
含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
|
CN105837584B
(zh)
|
2011-11-16 |
2018-07-13 |
吉利德制药有限责任公司 |
作为抗病毒化合物的缩合的咪唑基咪唑
|
ES2625518T3
(es)
|
2011-11-22 |
2017-07-19 |
The Regents Of The University Of California |
Beta-lactonas disustituidas como inhibidores de amidasa de ácido N-aciletanolamina (NAAA)
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
KR20140104030A
(ko)
|
2011-12-16 |
2014-08-27 |
에프. 호프만-라 로슈 아게 |
Hcv ns5a의 억제제
|
PE20141423A1
(es)
|
2011-12-20 |
2014-10-16 |
Hoffmann La Roche |
Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
|
HUE033332T2
(en)
|
2011-12-20 |
2017-11-28 |
Riboscience Llc |
4'-Azido-3'-fluoro-substituted nucleoside derivatives as inhibitors of HCV RNA replication
|
IN2014MN01465A
(nl)
*
|
2011-12-28 |
2015-04-17 |
Janssen R & D Ireland |
|
IN2014MN01486A
(nl)
|
2011-12-28 |
2015-04-24 |
Janssen R & D Ireland |
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
US9326973B2
(en)
*
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
IN2014MN01547A
(nl)
|
2012-02-10 |
2015-05-08 |
Lupin Ltd |
|
US9090559B2
(en)
|
2012-02-24 |
2015-07-28 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
EP2850072B1
(en)
|
2012-04-25 |
2016-08-31 |
Theravance Biopharma R&D IP, LLC |
Hepatitis c virus inhibitors
|
ME02682B
(me)
|
2012-04-25 |
2017-06-20 |
Theravance Biopharma R&D Ip Llc |
Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c
|
WO2013165796A1
(en)
|
2012-05-03 |
2013-11-07 |
Theravance, Inc. |
Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor
|
US20130309196A1
(en)
|
2012-05-16 |
2013-11-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2014065791A1
(en)
|
2012-10-24 |
2014-05-01 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
CA2892589A1
(en)
|
2013-01-23 |
2014-07-31 |
F. Hoffmann-La Roche Ag |
Antiviral triazole derivatives
|
LT2950786T
(lt)
|
2013-01-31 |
2020-03-10 |
Gilead Pharmasset Llc |
Dviejų antivirusinių junginių preparatų kompozicija
|
RU2507201C1
(ru)
|
2013-02-07 |
2014-02-20 |
Александр Васильевич Иващенко |
Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
|
TW201526899A
(zh)
|
2013-02-28 |
2015-07-16 |
Alios Biopharma Inc |
醫藥組成物
|
EP2964637B1
(en)
|
2013-03-05 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Antiviral compounds
|
US11484534B2
(en)
|
2013-03-14 |
2022-11-01 |
Abbvie Inc. |
Methods for treating HCV
|
WO2014144547A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
WO2014144836A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
|
WO2014175699A1
(ko)
*
|
2013-04-26 |
2014-10-30 |
서울대학교 산학협력단 |
벤지딘 유도체, 이의 제조방법 및 이를 함유하는 c형 간염 바이러스에 의한 간질환 치료용 약학적 조성물.
|
KR102241198B1
(ko)
|
2013-05-16 |
2021-04-15 |
리보사이언스 엘엘씨 |
4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
|
EA201592185A1
(ru)
|
2013-05-16 |
2016-05-31 |
Рибосайенс Ллк |
4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
WO2015026454A1
(en)
*
|
2013-07-17 |
2015-02-26 |
Bristol-Myers Squibb Company |
Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus
|
US9717712B2
(en)
|
2013-07-02 |
2017-08-01 |
Bristol-Myers Squibb Company |
Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
|
US20150023913A1
(en)
|
2013-07-02 |
2015-01-22 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
WO2015005901A1
(en)
*
|
2013-07-09 |
2015-01-15 |
Bristol-Myers Squibb Company |
Combinations of hepatitis c virus inhibitors
|
JP2016527232A
(ja)
*
|
2013-07-17 |
2016-09-08 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
KR101561964B1
(ko)
|
2013-11-15 |
2015-10-20 |
한국과학기술연구원 |
옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
|
US20160311806A1
(en)
*
|
2013-12-11 |
2016-10-27 |
Bristol-Myers Squibb Company |
4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors
|
WO2015089810A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
CA2943874A1
(en)
*
|
2014-04-04 |
2015-10-08 |
X-Rx, Inc. |
Substituted spirocyclic inhibitors of autotaxin
|
WO2015184644A1
(zh)
*
|
2014-06-06 |
2015-12-10 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的化合物、药物组合物及其应用
|
TWI721947B
(zh)
|
2014-06-11 |
2021-03-21 |
美商基利法瑪席特有限責任公司 |
抗病毒化合物的固態形式
|
EP3166852B1
(en)
|
2014-07-08 |
2018-03-28 |
GIMA S.p.A. |
Unit and method for filling containing elements of single-use capsules for extraction or infusion beverages.
|
WO2016075588A1
(en)
*
|
2014-11-11 |
2016-05-19 |
Sun Pharmaceutical Industries Limited |
Stable amorphous daclatasvir dihydrochloride
|
WO2016089814A1
(en)
|
2014-12-02 |
2016-06-09 |
Concert Pharmaceuticals, Inc. |
Deuterated analogues of daclatasvir
|
CN105753944B
(zh)
*
|
2014-12-19 |
2019-10-01 |
正大天晴药业集团股份有限公司 |
达卡他韦及其衍生物的制备中间体
|
EP3237405A1
(en)
|
2014-12-26 |
2017-11-01 |
Cipla Limited |
Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
|
CN106188015B
(zh)
*
|
2015-05-06 |
2019-10-18 |
广东东阳光药业有限公司 |
一种制备达卡他韦的方法
|
WO2016178250A1
(en)
|
2015-05-07 |
2016-11-10 |
Mylan Laboratories Limited |
Process for the preparation of daclatasvir
|
CZ2015366A3
(cs)
|
2015-05-29 |
2016-12-07 |
Zentiva, K.S. |
Pevné formy Daclatasviru
|
US20160375017A1
(en)
|
2015-06-26 |
2016-12-29 |
Abbvie Inc. |
Solid Pharmaceutical Compositions for Treating HCV
|
WO2017023631A1
(en)
|
2015-08-06 |
2017-02-09 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2017076358A1
(zh)
*
|
2015-11-06 |
2017-05-11 |
苏州晶云药物科技有限公司 |
咪唑基联苯基化合物盐的新晶型及其制备方法
|
GB2552919A
(en)
*
|
2015-11-18 |
2018-02-21 |
Azad Pharmaceutical Ingredients Ag |
Stable amorphous form of daclatasvir
|
CN106083829B
(zh)
*
|
2016-01-12 |
2019-01-22 |
深圳市塔吉瑞生物医药有限公司 |
一种丙型肝炎病毒抑制剂、药物组合物及其应用
|
US11186541B2
(en)
*
|
2016-03-28 |
2021-11-30 |
The University Of Toledo |
Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease
|
MX2020009947A
(es)
|
2016-04-07 |
2021-10-26 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas.
|
EP3448392A4
(en)
|
2016-04-28 |
2020-01-15 |
Emory University |
ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
|
WO2018007984A1
(en)
|
2016-07-08 |
2018-01-11 |
Lupin Limited |
Crystalline forms of daclatasvir dihydrochloride
|
WO2018015847A1
(en)
*
|
2016-07-18 |
2018-01-25 |
Glenmark Pharmaceuticals Limited |
Process for preparation of daclatasvir and salts
|
CN108069941A
(zh)
*
|
2016-11-15 |
2018-05-25 |
广东东阳光药业有限公司 |
一种制备达卡他韦的方法
|
RU2650610C1
(ru)
|
2017-02-28 |
2018-04-16 |
Васильевич Иващенко Александр |
Противовирусная композиция и способ ее применения
|
US10392370B2
(en)
*
|
2017-03-13 |
2019-08-27 |
Optimus Drugs Pvt Ltd |
Process for the preparation of Daclatasvir dihydrochloride and its intermediates
|
EP3604295A4
(en)
|
2017-03-22 |
2020-12-16 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
COMPOUND CONTAINING SILICON FOR RESISTANCE TO HEPATITIS C VIRUS INFECTION
|
CN109305962B
(zh)
*
|
2017-07-28 |
2022-01-18 |
扬子江药业集团有限公司 |
一种盐酸达拉他韦的精制方法
|
WO2019060740A1
(en)
|
2017-09-21 |
2019-03-28 |
Riboscience Llc |
4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
|
JP2022510407A
(ja)
|
2018-12-04 |
2022-01-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
WO2020219808A1
(en)
*
|
2019-04-25 |
2020-10-29 |
Beta Pharma, Inc. |
Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases
|
WO2024059005A1
(en)
*
|
2022-09-14 |
2024-03-21 |
Jnana Therapeutics Inc. |
Treating pku with correctors of mammalian slc6a19 function
|